Labcorp (LH) Q4 2025 earnings review
Strong Profitability Masks Biopharma Volatility
Labcorp delivered robust bottom-line growth in Q4, with Adjusted EPS rising 18% to $4.07 and margins expanding 120bps to 13.9%. However, top-line growth decelerated significantly to 5.6% (from 8.6% in Q3), weighed down by a sharp 13.5% contraction in Early Development revenue. While the Diagnostics engine remains steady and Central Labs is accelerating, the volatility in early-stage biopharma demand remains a drag. Management's 2026 guidance suggests a return to stable growth, projecting 9% EPS expansion at the midpoint.
🐂 Bull Case
Despite revenue deceleration, operational efficiency is delivering results. Adjusted Operating Income margin expanded 120 basis points YoY to 13.9%. Diagnostics margins specifically jumped 150 bps to 15.4%, driven by organic demand and effective cost management.
The Biopharma segment isn't all bad news. Central Laboratories revenue accelerated to 11.1% growth in Q4 (up from 10.3% in Q3), validating the durability of late-stage clinical trial demand.
🐻 Bear Case
Early Development revenue swung violently from growth earlier in the year to a 13.5% decline in Q4. This volatility introduces significant risk to the Biopharma segment's stability and suggests biotech funding headwinds persist.
Enterprise revenue growth slowed to 5.6% in Q4, the second consecutive quarter of deceleration. 2026 guidance midpoint (5.4%) implies this slower growth rate is the new baseline, down from the ~7% pace seen in FY25.
⚖️ Verdict: 🟢
Bullish. While the drop in Early Development is a concern, Labcorp proved it can expand earnings (+18%) even when a key segment stumbles. The core Diagnostics business is solid, Central Labs is accelerating, and 2026 guidance points to continued high-single-digit EPS growth.
Key Themes
Bifurcation in Biopharma
A dramatic divergence has opened within the Biopharma segment. Central Labs (late-stage) accelerated to 11.1% growth, while Early Development (pre-clinical/early-stage) collapsed 13.5%. This indicates that while large pharma demand remains robust, the speculative biotech market has frozen or faced severe delays.
Diagnostics Profitability Surge
Diagnostics Adjusted Operating Income jumped to $419M (+16.6% YoY), with margins expanding 150 basis points to 15.4%. Drivers included 4.1% organic revenue growth and the inclusion of Invitae. This segment remains the reliable cash engine, offsetting volatility elsewhere.
Free Cash Flow Compression
Q4 Free Cash Flow fell 26% YoY to $490M (vs $665M in 24Q4). Management cited 'working capital timing.' While FY25 FCF grew 10% overall, the Q4 drop warrants monitoring to ensure it is indeed a timing issue and not a degradation in collections.
Strategic M&A Continuation
The company continues to roll up health system assets. In Q4, they closed deals with Community Health Systems and Incyte Diagnostics, and announced a new Central Lab facility. Acquisitions added 1.2% to Q4 topline growth, a critical lever as organic growth in Biopharma faced headwinds.
Innovation Pipeline
New launches included the first FDA-cleared blood test for Alzheimer's and expanded MRD testing for cancer recurrence. While financially smaller than core volumes, these high-value tests are crucial for long-term mix improvement.
Other KPIs
Accelerating. Up 18% YoY, significantly outpacing revenue growth. Full year EPS of $16.44 landed at the very top end of the prior guidance range ($16.15-$16.50), demonstrating strong execution.
Stable. Up 9.2% YoY. Book-to-bill was 1.09, indicating demand is still replenishing revenue despite the drop in Early Development. Forecasted conversion of $2.66B over next 12 months provides visibility.
Stable. Up 5.5% YoY. Organic growth was 4.1%, showing resilience. This segment constitutes 77% of total revenue, providing a stable floor for the company.
Guidance
Decelerating. The midpoint of ~5.4% is below the 7.2% growth achieved in FY25. This likely reflects caution regarding the Early Development segment recovery.
Stable/Accelerating. Midpoint implies ~9% growth, consistent with the long-term algorithm. Management expects to drive earnings faster than revenue through margin expansion and share repurchases.
Accelerating. Midpoint represents ~7.4% growth over FY25 ($1.21B). Conversion remains strong.
Decelerating. Down from 6.0% achieved in FY25 (calculated from $3.1B segment revenue). This range confirms that the double-digit growth seen in Central Labs will likely be offset by continued weakness in Early Development.
Key Questions
Early Development Visibility
Early Development revenue swung from +20% in Q2 to -13.5% in Q4. What specific factors caused this rapid deterioration, and what gives confidence in the 3-5% segment growth guide for 2026?
Diagnostics Volume Durability
Organic volume growth in Diagnostics has been strong. With the respiratory season peaking, how should we think about normalization of volumes in H1 2026?
Working Capital & FCF
Q4 Free Cash Flow was down 26% YoY due to 'working capital timing.' Can you detail the specific accounts involved and when this timing difference is expected to reverse?